Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Puma Biotechnology stock | $10.55

Learn how to easily invest in Puma Biotechnology stock.

Puma Biotechnology, Inc
-$0.22 (-2.80%)

Puma Biotechnology, Inc is a biotechnology business based in the US. Puma Biotechnology shares (PBYI) are listed on the NASDAQ and all prices are listed in US Dollars. Puma Biotechnology employs 267 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Puma Biotechnology

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PBYI – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Puma Biotechnology stock price (NASDAQ: PBYI)

Use our graph to track the performance of PBYI stocks over time.

Puma Biotechnology shares at a glance

Information last updated 2021-07-23.
Latest market close$10.55
52-week range$7.48 - $14.14
50-day moving average $9.55
200-day moving average $10.41
Wall St. target price$9.57
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.41

Buy Puma Biotechnology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stocks, Options, ETFs
$0 per year
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Puma Biotechnology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Puma Biotechnology price performance over time

Historical closes compared with the close of $10.55 from 2021-05-28

1 week (2021-07-19) N/A
1 month (2021-06-30) 14.92%
3 months (2021-04-30) 7.00%
6 months (2021-01-26) N/A
1 year (2020-07-26) N/A
2 years (2019-07-26) N/A
3 years (2018-07-26) N/A
5 years (2016-07-26) N/A

Is Puma Biotechnology under- or over-valued?

Valuing Puma Biotechnology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Puma Biotechnology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Puma Biotechnology's PEG ratio

Puma Biotechnology's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.03. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Puma Biotechnology's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Puma Biotechnology's EBITDA

Puma Biotechnology's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $35.1 million.

The EBITDA is a measure of a Puma Biotechnology's overall financial performance and is widely used to measure a its profitability.

Puma Biotechnology financials

Revenue TTM $272.1 million
Operating margin TTM 8.82%
Gross profit TTM $185.7 million
Return on assets TTM 6.2%
Return on equity TTM -205.58%
Profit margin -9.75%
Book value $0.41
Market capitalisation $332.6 million

TTM: trailing 12 months

Shorting Puma Biotechnology shares

There are currently 2.7 million Puma Biotechnology shares held short by investors – that's known as Puma Biotechnology's "short interest". This figure is 28.4% down from 3.8 million last month.

There are a few different ways that this level of interest in shorting Puma Biotechnology shares can be evaluated.

Puma Biotechnology's "short interest ratio" (SIR)

Puma Biotechnology's "short interest ratio" (SIR) is the quantity of Puma Biotechnology shares currently shorted divided by the average quantity of Puma Biotechnology shares traded daily (recently around 446941.12769486). Puma Biotechnology's SIR currently stands at 6.03. In other words for every 100,000 Puma Biotechnology shares traded daily on the market, roughly 6030 shares are currently held short.

However Puma Biotechnology's short interest can also be evaluated against the total number of Puma Biotechnology shares, or, against the total number of tradable Puma Biotechnology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Puma Biotechnology's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Puma Biotechnology shares in existence, roughly 70 shares are currently held short) or 0.0908% of the tradable shares (for every 100,000 tradable Puma Biotechnology shares, roughly 91 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Puma Biotechnology.

Find out more about how you can short Puma Biotechnology stock.

Puma Biotechnology share dividends

We're not expecting Puma Biotechnology to pay a dividend over the next 12 months.

Puma Biotechnology share price volatility

Over the last 12 months, Puma Biotechnology's shares have ranged in value from as little as $7.48 up to $14.14. A popular way to gauge a stock's volatility is its "beta".

PBYI.US volatility(beta: 1.24)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Puma Biotechnology's is 1.2448. This would suggest that Puma Biotechnology's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Puma Biotechnology overview

Puma Biotechnology, Inc. , a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc. ; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd. , CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc. , Pierre Fabre Medicament SAS, and Bixink Therapeutics Co.

Stocks similar to Puma Biotechnology

Frequently asked questions

What percentage of Puma Biotechnology is owned by insiders or institutions?
Currently 13.59% of Puma Biotechnology shares are held by insiders and 95.88% by institutions.
How many people work for Puma Biotechnology?
Latest data suggests 267 work at Puma Biotechnology.
When does the fiscal year end for Puma Biotechnology?
Puma Biotechnology's fiscal year ends in December.
Where is Puma Biotechnology based?
Puma Biotechnology's address is: 10880 Wilshire Boulevard, Los Angeles, CA, United States, 90024
What is Puma Biotechnology's ISIN number?
Puma Biotechnology's international securities identification number is: US74587V1070
What is Puma Biotechnology's CUSIP number?
Puma Biotechnology's Committee on Uniform Securities Identification Procedures number is: 74587V107

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site